Atle Fund Management AB Purchases 5,004 Shares of Gilead Sciences, Inc. $GILD

Atle Fund Management AB grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 78,169 shares of the biopharmaceutical company’s stock after buying an additional 5,004 shares during the period. Gilead Sciences accounts for about 3.4% of Atle Fund Management AB’s investment portfolio, making the stock its 10th biggest holding. Atle Fund Management AB’s holdings in Gilead Sciences were worth $8,677,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Norges Bank bought a new stake in shares of Gilead Sciences during the second quarter valued at about $2,150,268,000. Ameriprise Financial Inc. increased its stake in Gilead Sciences by 397.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company’s stock valued at $748,147,000 after buying an additional 5,392,191 shares during the period. Invesco Ltd. raised its position in shares of Gilead Sciences by 33.5% during the 2nd quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock worth $1,499,098,000 after buying an additional 3,394,330 shares in the last quarter. Assenagon Asset Management S.A. raised its position in shares of Gilead Sciences by 164.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 3,489,062 shares of the biopharmaceutical company’s stock worth $387,286,000 after buying an additional 2,169,266 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in shares of Gilead Sciences by 1.6% in the 2nd quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock worth $13,233,912,000 after acquiring an additional 1,893,401 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Stock Performance

Shares of GILD opened at $141.95 on Friday. The company has a 50-day moving average of $125.36 and a two-hundred day moving average of $119.67. The stock has a market cap of $176.11 billion, a price-to-earnings ratio of 22.01, a PEG ratio of 0.73 and a beta of 0.33. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. Gilead Sciences, Inc. has a one year low of $93.37 and a one year high of $142.20.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The business had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. During the same quarter in the prior year, the firm earned $2.02 EPS. The firm’s quarterly revenue was up 3.0% on a year-over-year basis. On average, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Leerink Partners raised their price objective on shares of Gilead Sciences from $114.00 to $146.00 and gave the company an “outperform” rating in a research note on Friday. Rothschild & Co Redburn increased their price target on Gilead Sciences from $153.00 to $159.00 and gave the company a “buy” rating in a research note on Tuesday, January 20th. Sanford C. Bernstein set a $135.00 price objective on Gilead Sciences and gave the stock an “outperform” rating in a research note on Monday, December 29th. Citigroup raised their target price on Gilead Sciences from $140.00 to $156.00 and gave the company a “buy” rating in a research note on Tuesday, January 27th. Finally, HSBC lifted their target price on Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a report on Wednesday, December 10th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $136.73.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Multiple sell‑side firms raised targets and reiterated bullish ratings (Wolfe Research to $155/outperform; TD Cowen to $145/buy), reinforcing buy-side momentum and implied upside from current levels. Read More. Read More.
• Positive Sentiment: Broader analyst upgrades/positive notes from Citi, Truist, BMO and UBS add to consensus bullishness, supporting demand and higher valuation multiples. Read More.
• Positive Sentiment: Clinical/regulatory wins for Trodelvy (added to NCCN guidelines; TNBC approval/win coverage) strengthen Gilead’s oncology growth story and revenue optionality beyond antivirals. Read More. Read More.
• Positive Sentiment: Coverage pieces noting that GILD has outperformed the market and is attracting analyst attention can draw momentum and ETF/quant flows into the stock. Read More.
• Neutral Sentiment: Notes on GILD’s presence in Nasdaq/healthcare ETF lineups and elevated investor attention increase volume and liquidity but are not clear directional catalysts by themselves. Read More.
• Negative Sentiment: Insider selling: CEO Daniel Patrick O’Day sold 10,000 shares (~$1.4M) at ~$139.89 (filed on Form 4). While modest relative to his remaining holding and potentially routine, insider sales can be interpreted negatively by some investors. Read More.

Insider Activity at Gilead Sciences

In other news, Director Kelly A. Kramer sold 2,805 shares of the firm’s stock in a transaction on Friday, November 28th. The stock was sold at an average price of $127.10, for a total value of $356,515.50. Following the completion of the sale, the director owned 1,339 shares of the company’s stock, valued at $170,186.90. This trade represents a 67.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $124.31, for a total value of $372,930.00. Following the transaction, the chief financial officer directly owned 150,503 shares in the company, valued at $18,709,027.93. The trade was a 1.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 257,397 shares of company stock worth $33,385,512. Insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.